Private Trust Co. NA Increases Holdings in Sanofi $SNY

Private Trust Co. NA increased its stake in shares of Sanofi (NASDAQ:SNY) by 37.6% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 5,808 shares of the company’s stock after acquiring an additional 1,588 shares during the quarter. Private Trust Co. NA’s holdings in Sanofi were worth $281,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Sagespring Wealth Partners LLC lifted its position in Sanofi by 27.5% during the second quarter. Sagespring Wealth Partners LLC now owns 14,689 shares of the company’s stock worth $710,000 after buying an additional 3,167 shares in the last quarter. Concord Wealth Partners lifted its position in Sanofi by 510.3% during the second quarter. Concord Wealth Partners now owns 885 shares of the company’s stock worth $43,000 after buying an additional 740 shares in the last quarter. Sequoia Financial Advisors LLC lifted its position in Sanofi by 14.0% during the second quarter. Sequoia Financial Advisors LLC now owns 27,677 shares of the company’s stock worth $1,337,000 after buying an additional 3,405 shares in the last quarter. Yousif Capital Management LLC lifted its position in Sanofi by 11.3% during the second quarter. Yousif Capital Management LLC now owns 66,980 shares of the company’s stock worth $3,236,000 after buying an additional 6,789 shares in the last quarter. Finally, CWM LLC lifted its position in Sanofi by 4.4% during the second quarter. CWM LLC now owns 113,325 shares of the company’s stock worth $5,475,000 after buying an additional 4,815 shares in the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Barclays reiterated an “overweight” rating on shares of Sanofi in a research report on Wednesday, July 2nd. Morgan Stanley upgraded Sanofi from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $56.00 to $58.00 in a research report on Monday, September 8th. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a research report on Wednesday, October 8th. JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $62.67.

Sanofi Trading Down 1.8%

SNY opened at $49.73 on Tuesday. Sanofi has a one year low of $44.62 and a one year high of $60.12. The company has a market cap of $122.11 billion, a P/E ratio of 11.95, a PEG ratio of 1.23 and a beta of 0.51. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. The business’s 50-day simple moving average is $48.54 and its 200-day simple moving average is $49.55.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The firm had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. During the same period last year, the company earned $1.73 earnings per share. The firm’s revenue for the quarter was down 7.0% compared to the same quarter last year. As a group, equities research analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.